Extrapolation of indications for mAbs

2016-11-02 Monoclonal antibody (mAb) biosimilars have recently entered the market, raising questions in the healthcare community. One of the questions discussed by Professor Pierre Michetti, a… Read More »

Impact of hypertension generics in Europe

2016-10-28 A report by the Germany-based Institute for Healthcare and Social Research (IGES) released in November 2015 found that generics of drugs to treat high blood… Read More »

Beyond biosimilarity

2016-10-26 The advent of monoclonal antibody (mAb) biosimilars has raised a series of questions in the healthcare community. Just a few of these questions were discussed… Read More »

Perception and knowledge of generics in Portugal

2016-10-24 Patients in Portugal are misinformed about generics, according to researchers from the Bragança Polytechnic Institute [1]. The study by Maria Ribeiro and co-authors analysed the… Read More »

Efficacy and safety of biosimilar infliximab compared to other biologicals in rheumatoid arthritis

2016-10-21 In the paper by Baji et al. [1], the authors carried out a meta-analysis to compare the efficacy and safety of biosimilar infliximab and other… Read More »

FDA includes follow-on versions in its new liposome guideline

2016-10-19 On 29 October 2015, the US Food and Drug Administration (FDA) issued a new draft guidance document for non-biological complex drugs (NBCDs). The new draft… Read More »

Measures to increase generics use in Greece

2016-10-17 Austerity has forced Greece to introduce a number of measures to reduce the amount it spends on healthcare. But how have measures aimed at increasing… Read More »

BSG guidance recommends switching to biosimilar infliximab

2016-10-14 The British Society of Gastroenterology (BSG) released new guidance in February 2016 recommending that stable patients be switched to biosimilar infliximab (CT-P13). Biosimilar infliximab, Remisima/Inflectra… Read More »

Consumer choice between generic and brand-name medicines in a small generics market

2016-10-12 Background Generics offer an opportunity to governments to contain pharmaceutical expenditures, as they are generally 10‒80% lower in price than the originator brand-name medicines. Belgium… Read More »

Differences between biosimilars and reference products

2016-10-10 A review of glycosylated biosimilars approved in the European Union (EU) and Japan has highlighted structural variances between biosimilars and their reference products [1]. Biosimilars… Read More »

Page 4 of 48 1 ... « Previous2 3 4 5 6 Next »... 48
Go Back Print